Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 8:15:1487782.
doi: 10.3389/fimmu.2024.1487782. eCollection 2024.

Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment

Jianing Li  1 , Yongsheng Zhang  2 , Tong Fu  3 , Guoli Xing  4 , Hongbo Cai  4 , Kaiqing Li  1 , Yutong Xu  1 , Ying Tong  4
Affiliations
Review

Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment

Jianing Li et al. Front Immunol. .

Abstract

Background: T cell receptor (TCR)-T cell therapy is an innovative form of cancer immunotherapy that genetically modifies patients' T cells to target and destroy cancer cells. However, the current status of clinical trials of TCR-T cell therapy for the treatment of cancer remains unclear. This study aimed to comprehensively analyze the registration trials related to TCR-T cell therapy for the treatment of cancer.

Methods: A comprehensive search was conducted in the Trialtrove database for all clinical trials related to TCR-T cell therapy registered by August 1, 2024. Inclusion criteria focused on trials targeting TCR-T cell therapy for oncology, and excluded observational studies and incomplete data. Statistical analysis was performed on key trial characteristics, with between-group comparisons utilizing chi-square or Fisher's exact tests.

Results: Analysis of 174 eligible clinical trials revealed that TCR-T cell therapy exhibits significant efficacy across various tumor types, particularly in refractory hematologic malignancies and certain solid tumors. Additionally, combining TCR-T cell therapy with other immunotherapies enhanced these anti-tumor effects.

Conclusion: TCR-T cell therapy holds substantial promise for cancer treatment. Future research should focus on optimizing treatment protocols, enhancing efficacy, and minimizing prices to fully realize the potential of this therapy.

Keywords: TCR-T cell therapy; cancer; cancer immunotherapy; clinical trials; genetic engineering; therapeutic resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Start date distribution of clinical trials for TCR-T cell therapy in cancer treatment.
Figure 2
Figure 2
Global distribution of clinical trials for TCR-T cell therapy in cancer treatment.
Figure 3
Figure 3
Funding types in research projects.
Figure 4
Figure 4
Trial phase and trial status distribution of clinical trials for TCR-T cell therapy in cancer treatment.
Figure 5
Figure 5
Allocation distribution of clinical trials for TCR-T cell therapy in cancer treatment.
Figure 6
Figure 6
Masking distribution of clinical trials for TCR-T cell therapy in cancer treatment.
Figure 7
Figure 7
Disease and targets distribution of clinical trials for TCR-T cell therapy in cancer treatment.
See this image and copyright information in PMC

References

    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013 - DOI - PubMed
    1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. (2012) 13:790–801. doi: 10.1016/S1470-2045(12)70211-5 - DOI - PubMed
    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. (2023) 73:17–48. doi: 10.3322/caac.21763 - DOI - PubMed
    1. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. (2013) 19:5300–9. doi: 10.1158/1078-0432.CCR-13-0143 - DOI - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. (2005) 352:987–96. doi: 10.1056/NEJMoa043330 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources